Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesFesoterodine for the treatment of urinary incontinence and overactive bladder
Therapeutics and Clinical Risk Management, 11/04/09
Ellsworth P – Fesoterodine is one of the newest antimuscarinic agent approved for the management of OAB. It is unique in that it shares the same active metabolite as tolterodine, 5–hydoxymethyltolterodine (5–HMT); however, this conversion is established via ubiquitous esterases and not via the cytochrome P450 system, thus providing a faster and more efficient conversion to 5–HMT. Fesoterodine is available in 2 doses, 4 mg and 8 mg. Clinical trials have established a dose response relationship in efficacy parameters as well as improvements in quality of life. As with all antimuscarinics, dry mouth and constipation are the more common side effects. A combination of medical therapy and behavioral therapy improves the overall outcome in management of OAB. Dose flexibility may help improve efficacy outcomes and patient education on the management of common adverse effects may improve tolerability with these agents.
Related Articles
Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity
BJU International, 11/11/09
Relevance Score: 82%
Fesoterodine: a new antimuscarinic for overactive bladder
Aging Health, 10/13/09
Relevance Score: 79%
Prevalence and Severity of Undiagnosed Urinary Incontinence in Women
American Journal of Medicine, 10/27/09
Relevance Score: 71%
Etiology and predictors of urinary incontinence and its effect on quality of life
Geriatrics and Gerontology International, 11/17/09
Relevance Score: 70%
Urinary Incontinence Therapy Area Pipeline Report
Internet Source, 10/30/09
Relevance Score: 70%
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization
Current Medical Research and Opinion, 11/25/09
Anti-relapse medications: Preclinical models for drug addiction treatment
Pharmacology & Therapeutics, 11/25/09
Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Diabetes Research and Clinical Practice, 11/25/09
Sponsor
Article Search
Sponsor